NEW ORLEANS —Pruritus could be a reliable indicator of inflammation in central centrifugal cicatricial alopecia, according to a poster presented here.“[Central centrifugal cicatricial alopecia (CCCA)] is a type of scarring baldness that predominately affects black women,” Aditi Gadre, MS, the 2022-2023 Ethnic Skin Research Fellow at Johns Hopkins University and the study’s
NEW ORLEANS — Patients with atopic dermatitis experienced a rapid and sustained reduction in itch with topical roflumilast cream treatment, according to phase 3 study results presented at the American Academy of Dermatology Annual Meeting.“The study supports that roflumilast cream 0.15% showed efficacy, good safety and very good tolerance for children and adults with atopic dermatitis
NEW ORLEANS — Phase 2b clinical trial results of Takeda Pharmaceuticals’ novel tyrosine kinase 2 inhibitor found significantly greater skin clearance in study patients compared with placebo, according to a presentation here.
In the phase 2b, randomized, double-blind, placebo-controlled study, April W. Armstrong, MD, MPH, FAAD, professor of dermatology and associate dean for clinical
NEW ORLEANS — Although Black patients with atopic dermatitis treated with dupilumab experienced fewer adverse events than their white counterparts, the difference did not reach statistical significance, according to a poster presented here.
“We wanted to look at what the adverse events were, but also, what is the breakdown when you look at it by race,” Tatiana M. Barrera, BA, a
DENVER — A cream with heparin sulfate analog successfully reduced erythema in patients with rosacea, according to a study presented here.“Rosacea is chronic inflammatory skin condition that results in recurrent flushing, central facial erythema and telangiectasia,” Rosalyn George, MD, of the Wilmington Dermatology Center, said during a video abstract presentation. “These